Segment 3 trial reinforces the suitability of roflumilast cream 0.05% for atopic dermatitis in youngsters
Certain effects from the Segment 3 INTEGUMENT-PED trial confirmed that youngsters elderly 2 to five years with atopic dermatitis who have been handled with roflumilast cream 0.05% had important development…